On December 11, 2025, Genting Xinyao, a Hong Kong stock innovative pharmaceutical company, announced that its wholly-owned subsidiary Genting Xinyao Pharmaceutical Technology Co., Ltd. has signed two strategic cooperation agreements with Hisense Biomedical Co., Ltd.: a commercial service agreement and a licensing agreement. The two agreements will have significant financial and strategic synergy effects, enhance the operational efficiency of existing commercial platforms, accelerate commercialization capacity building for the full life cycle and omni-channel coverage of Genting Xinyao products, and create an attractive business layout for the company in the field of cardiovascular diseases.

On December 11, 2025, Genting Xinyao, a Hong Kong stock innovative pharmaceutical company, announced that its wholly-owned subsidiary Genting Xinyao Pharmaceutical Technology Co., Ltd. has signed two strategic cooperation agreements with Hisense Biomedical Co., Ltd.: a commercial service agreement and a licensing agreement. The two agreements will have significant financial and strategic synergy effects, enhance the operational efficiency of existing commercial platforms, accelerate commercialization capacity building for the full life cycle and omni-channel coverage of Genting Xinyao products, and create an attractive business layout for the company in the field of cardiovascular diseases.